BACKGROUND: The concept of "accelerated" chronic lymphocytic leukemia is frequently used by both pathologists and clinicians. However, neither histological criteria to define this form of chronic lymphocytic leukemia nor its clinical correlates and prognostic impact have been formally defined in large series of patients. DESIGN AND METHODS: Tissue biopsies from 100 patients with chronic lymphocytic leukemia were analyzed for the size of proliferation centers and their proliferation rate as assessed by mitosis count and Ki-67 immunostaining. Histological patterns were correlated with main clinico-biological features and outcome. RESULTS: A suspicion of disease transformation was the main reason for carrying out tissue biopsy, which was performed at a median time of 14 months (range, 0 to 204 months) after the diagnosis of chronic lymphocytic leukemia. The biopsy showed histological transformation to diffuse large B-cell lymphoma in 22 cases. In the remaining 78 patients, the presence of expanded proliferation centers (broader than a 20x field) and high proliferation rate (either >2.4 mitoses/proliferation center or Ki-67 >40%/proliferation center) predicted a poor outcome and were selected to define a highly proliferative group. Thus, 23 patients with either expanded proliferation centers or high proliferation rate were considered as having "accelerated" chronic lymphocytic leukemia. These patients displayed particular features, including higher serum lactate dehydrogenase levels and more frequently elevated ZAP-70 than "non-accelerated" cases. The median survival from biopsy of patients with "non-accelerated" chronic lymphocytic leukemia, "accelerated" chronic lymphocytic leukemia and transformation to diffuse large B-cell leukemia was 76, 34, and 4.3 months, respectively (P<0.001). CONCLUSIONS: The presence of expanded and/or highly active proliferation centers identifies a group of patients with "accelerated" chronic lymphocytic leukemia characterized by an aggressive clinical behavior.
BACKGROUND: The concept of "accelerated" chronic lymphocytic leukemia is frequently used by both pathologists and clinicians. However, neither histological criteria to define this form of chronic lymphocytic leukemia nor its clinical correlates and prognostic impact have been formally defined in large series of patients. DESIGN AND METHODS: Tissue biopsies from 100 patients with chronic lymphocytic leukemia were analyzed for the size of proliferation centers and their proliferation rate as assessed by mitosis count and Ki-67 immunostaining. Histological patterns were correlated with main clinico-biological features and outcome. RESULTS: A suspicion of disease transformation was the main reason for carrying out tissue biopsy, which was performed at a median time of 14 months (range, 0 to 204 months) after the diagnosis of chronic lymphocytic leukemia. The biopsy showed histological transformation to diffuse large B-cell lymphoma in 22 cases. In the remaining 78 patients, the presence of expanded proliferation centers (broader than a 20x field) and high proliferation rate (either >2.4 mitoses/proliferation center or Ki-67 >40%/proliferation center) predicted a poor outcome and were selected to define a highly proliferative group. Thus, 23 patients with either expanded proliferation centers or high proliferation rate were considered as having "accelerated" chronic lymphocytic leukemia. These patients displayed particular features, including higher serum lactate dehydrogenase levels and more frequently elevated ZAP-70 than "non-accelerated" cases. The median survival from biopsy of patients with "non-accelerated" chronic lymphocytic leukemia, "accelerated" chronic lymphocytic leukemia and transformation to diffuse large B-cell leukemia was 76, 34, and 4.3 months, respectively (P<0.001). CONCLUSIONS: The presence of expanded and/or highly active proliferation centers identifies a group of patients with "accelerated" chronic lymphocytic leukemia characterized by an aggressive clinical behavior.
Authors: Rajendra N Damle; Fabio Ghiotto; Angelo Valetto; Emilia Albesiano; Franco Fais; Xiao-Jie Yan; Cristina P Sison; Steven L Allen; Jonathan Kolitz; Philip Schulman; Vincent P Vinciguerra; Petra Budde; Jurgen Frey; Kanti R Rai; Manlio Ferrarini; Nicholas Chiorazzi Journal: Blood Date: 2002-06-01 Impact factor: 22.113
Authors: L Granziero; P Ghia; P Circosta; D Gottardi; G Strola; M Geuna; L Montagna; P Piccoli; M Chilosi; F Caligaris-Cappio Journal: Blood Date: 2001-05-01 Impact factor: 22.113
Authors: H Döhner; S Stilgenbauer; A Benner; E Leupolt; A Kröber; L Bullinger; K Döhner; M Bentz; P Lichter Journal: N Engl J Med Date: 2000-12-28 Impact factor: 91.245
Authors: F Cobo; A Martínez; M Pinyol; L Hernández; M Gómez; S Beá; J Esteve; M Rozman; F Bosch; A López-Guillermo; E Montserrat; E Campo Journal: Leukemia Date: 2002-06 Impact factor: 11.528
Authors: Eileen Y Hu; James S Blachly; Caner Saygin; Hatice G Ozer; Stephanie E Workman; Arletta Lozanski; Tzyy-Jye Doong; Chi-Ling Chiang; Seema Bhat; Kerry A Rogers; Jennifer A Woyach; Kevin R Coombes; Daniel Jones; Natarajan Muthusamy; Gerard Lozanski; John C Byrd Journal: JCI Insight Date: 2020-06-18
Authors: Sarah E M Herman; Amber L Gordon; Erin Hertlein; Asha Ramanunni; Xiaoli Zhang; Samantha Jaglowski; Joseph Flynn; Jeffrey Jones; Kristie A Blum; Joseph J Buggy; Ahmed Hamdy; Amy J Johnson; John C Byrd Journal: Blood Date: 2011-03-21 Impact factor: 22.113
Authors: Mariam Hammadi; Pierre Youinou; Adrian Tempescul; Gabriel Tobón; Christian Berthou; Anne Bordron; Jacques-Olivier Pers Journal: Haematologica Date: 2011-11-04 Impact factor: 9.941
Authors: Lorenzo Falchi; Michael J Keating; Edith M Marom; Mylene T Truong; Ellen J Schlette; Rachel L Sargent; Long Trinh; Xuemei Wang; Susan C Smith; Nitin Jain; Zeev Estrov; Susan O'Brien; William G Wierda; Susan Lerner; Alessandra Ferrajoli Journal: Blood Date: 2014-03-10 Impact factor: 22.113
Authors: Michael J Conte; Deborah A Bowen; Gregory A Wiseman; Kari G Rabe; Susan L Slager; Susan M Schwager; Timothy G Call; David S Viswanatha; Clive S Zent Journal: Leuk Lymphoma Date: 2014-02-17
Authors: Alexandra Valera; Armando López-Guillermo; Teresa Cardesa-Salzmann; Fina Climent; Eva González-Barca; Santiago Mercadal; Iñigo Espinosa; Silvana Novelli; Javier Briones; José L Mate; Olga Salamero; Juan M Sancho; Leonor Arenillas; Sergi Serrano; Nadina Erill; Daniel Martínez; Paola Castillo; Jordina Rovira; Antonio Martínez; Elias Campo; Luis Colomo Journal: Haematologica Date: 2013-05-28 Impact factor: 9.941
Authors: Naveen Pemmaraju; Preetesh Jain; L Jeffrey Medeiros; Jeffrey L Jorgenson; Nitin Jain; Jason Willis; Dimitrios P Kontoyiannis; Zeev Estrov; William G Wierda Journal: Am J Hematol Date: 2017-02-07 Impact factor: 10.047